|
Pre-radiation
Chemotherapy for Malignant Glioma in Adults
Sarah Kirby, David Macdonald, Barbara Fisher, Laurie Gaspar
and Gregory Cairncross
Abstract:
Purpose: To review our experience with
pre-radiation chemotherapy for malignant glioma. Methods:
Consecutive adults with newly diagnosed glioblastoma, anaplastic
astrocytoma, anaplastic oligodendroglioma and anaplastic mixed
glioma with a Karnofsky Performance Score of 60 or greater were
treated with one cycle of procarbazine, lomustine and vincristine
or lomustine alone, prior to radiation. Computed tomographic
scans were obtained soon after surgery, eight weeks later, after
radiation, and at regular intervals thereafter. The effects
of chemotherapy and subsequent radiation and durations of tumor
control and survival were assessed in this single arm, single
center, prospective trial. Results: Thirty-seven
patients started chemotherapy, 36 were rescanned eight weeks
after diagnosis. Five patients (16%) responded to the first
cycle of chemotherapy, three had glioblastoma and two anaplastic
oligodendroglioma. Seven (19%) progressed during the first cycle,
6 had glioblastoma; with the addition of radiation one progressive
case responded, three stabilized, and three continued to progress.
Median times to progression and median durations of survival
were 26 weeks and 60 weeks for the entire group, 24 weeks and
44 weeks for glioblastoma, and greater than 104 weeks for anaplastic
astrocytoma. Conclusions: Most patients with glioblastoma
do not respond to one cycle of nitrosourea-based chemotherapy
given prior to radiation, but patients with anaplastic oligodendroglioma
sometimes do. Patients with anaplastic astrocytoma may not respond
to one cycle of chemotherapy, but often respond to subsequent
radiation. Judging by survival results, radiation can be delayed
eight weeks without appearing to compromise patient outcome.
Implications: Pre-radiation chemotherapy with
newer agents can be evaluated more fully in the future knowing
that brief delays in radiation are unlikely to yield substantially
inferior results.
|
Can.
J. Neurol. Sci. 1996; 23: 123-127
|
|